Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct;8(6):2425–2438. doi: 10.21037/tcr.2019.09.61

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2019 Translational Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Combination of AXL inhibition and erlotinib treatment significantly repressed the migration of HCC827-ER3 cells. (A) Representative images from in vitro scratch wound healing assays in HCC827-ER3 cells treated with erlotinib and/or MDCG625. (B) The bar graph illustrates the percentage of wound closure at indicated time points during the scratch wound assay. *, P<0.05. (C) HCC827-ER3 cells were treated as described above. Cell lysates were prepared and subjected to immunoblot analysis with EMT marker antibodies including E-cadherin, vimentin, Snail and GAPDH.